- BioStratum has achieved its goal of developing a recombinant,functional form of a laminin molecule. Laminins are complex extracellular proteins which may have utility in the treatment of deep wounds, severe burns or traumatic injury of nerves and blood vessels. BioStratum has already signed an agreement with Shiseido of Japan to develop skin regeneration products based on laminin-5. The company is also working on laminin-2 and laminin-8, which target nerves and blood vessels respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze